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Abstract
Background:  We aimed to study the effects of intra-articular injection of jellyfish mucin
(qniumucin) on articular cartilage degeneration in a model of osteoarthritis (OA) created in rabbit
knees by resection of the anterior cruciate ligament. Qniumucin was extracted from Aurelia aurita
(moon jellyfish) and Stomolophus nomurai (Nomura's jellyfish) and purified by ion exchange
chromatography. The OA model used 36 knees in 18 Japanese white rabbits. Purified qniumucin
extracts from S. nomurai or A. aurita were used at 1 mg/ml. Rabbits were divided into four groups:
a control (C) group injected with saline; a hyaluronic acid (HA)-only group (H group); two
qniumucin-only groups (M groups); and two qniumucin + HA groups (MH groups). One milligram
of each solution was injected intra-articularly once a week for 5 consecutive weeks, starting from
4 weeks after surgery. Ten weeks after surgery, the articular cartilage was evaluated
macroscopically and histologically.
Results: In the C and M groups, macroscopic cartilage defects extended to the subchondral bone
medially and laterally. When the H and both MH groups were compared, only minor cartilage
degeneration was observed in groups treated with qniumucin in contrast to the group without
qniumucin. Histologically, densely safranin-O-stained cartilage layers were observed in the H and
two MH groups, but cartilage was strongly maintained in both MH groups.
Conclusion: At the concentrations of qniumucin used in this study, injection together with HA
inhibited articular cartilage degeneration in this model of OA.
Background
Osteoarthritis (OA) is one of the most common joint dis-
eases and is characterized by the gradual degeneration of
cartilage over a long time (regressive degeneration). This
disease commonly develops in the weight-bearing joints
of the lower limbs, such as the knee and hip joints, and
onset shows a close correlation closely with age. OA is
thus one of the main causes of pain and joint dysfunction
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among the elderly, and is also often seen in young people
after traumas such as a fracture, anterior cruciate ligament
transection (ACL-T), meniscus injury or in the presence of
an underlying disease such as hemophilia [1]. Currently,
pharmacotherapies for OA focus mainly on the allevia-
tion of pain and consist of systemic analgesic therapies
and local intra-articular treatments. Nonsteroidal anti-
inflammatory drugs (NSAIDs) are widely used as systemic
analgesic therapies [2]. However, pathological progres-
sion of OA can be accelerated by the use of NSAIDs [3-6].
Similarly, hyaluronan (HA) injection therapy is a widely
recognized part of local intra-articular treatments, inhibit-
ing the destruction of articular cartilage by increasing the
viscosity of synovial fluid [7-10].
The presence of a thin membrane layer on the articular
cartilage surface is believed to protect against external
impact and reduce friction. This membrane is formed
from glycoproteins with a mucin-type domain, some of
which have been identified in humans, including tri-
bonectin and lubricin [11,12]. These glycoproteins in the
joints show tandem repeat regions composed of 7-8
amino acids in the mucin domain; more than 90% of the
threonines and serines can form O-glycosyl bonds and are
glycosylated. The sugar chains are short, consisting of 2-3
monosaccharides (including sialic acid), with very little
diversity (glycoforms) in the sugar chains. These mucins
display characteristics very similar to those of qniumucin,
the jellyfish mucin analyzed in this study.
At present, no methods have been established to produce
mucins artificially on a sufficiently large scale for thera-
peutic use. Chemical synthesis is not very practical, as the
cost of producing a mucin-type polymer is high, even
when the structure is very simple. Although O-glycosyla-
tion is a typical posttranslational modification in biologi-
cal systems, occurring in the Golgi apparatus, synthetic
versions of this procedure, in which sugar chains are
attached after the expression of core proteins, can only be
performed in a limited manner. Under these circum-
stances, extraction of natural abundant mucins from
organisms is most often used. In the industrial production
of mucins, only extraction from the gastric juices or saliva
of domestic animals has proven commercially successful.
However, the purity and homogeneity of these mucins are
insufficient for use as a single substance and they have
been further avoided since the discovery of bovine spong-
iform encephalopathy (BSE) [13]. Mucins have also been
extracted from marine creatures, such as starfish [14] and
squid [15], but this technique is also ineffective in terms
of efficiency and cost.
Stomolophus nomurai is the world's largest jellyfish, grow-
ing to over 1 m in diameter and weighing more than 200
kg (Fig. 1). Vast proliferation of this species has been
reported in the coastal regions of the Sea of Japan. Massive
smacks of jellyfish (about 100 tons on 1 day at one site)
are caught in fishing nets, significantly interfering with the
fishing industry. Removal of these jellyfish has now
become a routine practice for power plants, industrial
facilities, fisheries and harbors in coastal areas, and han-
dling such large quantities of jellyfish is extremely diffi-
cult. On the positive side, Ushida et al. have discovered
and successfully isolated a novel mucin derived from
many species of jellyfish, including S. nomurai [16]. This
compound, qniumucin, is low in diversity and high in
purity and constitutes an exceptional mucin that can be
obtained industrially as a homogeneous product.
In this study, we discuss the effects of intra-articular injec-
tion of qniumucin on cartilage degeneration in a rabbit
model of OA.
Results
Macroscopic study
Advanced cartilage defects extending to the subchondral
bone were observed on both the medial and lateral sides
in group C (Fig. 2a). Similar results were observed in
group M, with no apparent differences between groups C
and M (Fig. 2a, c, d). In a comparison of groups H and
MH, less cartilage degeneration was observed in the
groups treated with qniumucin and HA than in the group
treated with HA alone (Fig. 2b, e, f).
Histological study
Exposure of subchondral bone was detected by safranin-
O staining in group C (Fig. 3a). No cartilaginous layer
with metachromasia shown by toluidine blue staining
was observed in group C (Fig. 3g). Fissures in the cartilage
Nomura's jellyfish Figure 1
Nomura's jellyfish. The world's largest jellyfish, growing to 
over 1 m in diameter and weighing more than 200 kg.BMC Biotechnology 2009, 9:98 http://www.biomedcentral.com/1472-6750/9/98
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layers and reduced stainability were observed in group H
(Fig. 3b). Slight metachromasia in the cartilage layer was
observed in group H (Fig. 3h). In group M, minimal resid-
ual cartilage layers were present, but no staining was
observed and the cartilage cells had been destroyed (Fig.
3c, d). As in group C, no metachromatic cartilage layer
was observed in group M (Fig. 3i, j). Erosion of the carti-
lage, fissures and reduced staining were observed in group
MH. However, compared with group H, the fissures were
shallower and more cells were present (Fig. 3e, f). No met-
achromasia was observed in the cartilage layer in group
MH (Fig. 3k, l).
Average OA scores were: group C, 22.00 ± 4.00; group H,
11.17 ± 4.65; group M1, 18.67 ± 1.15; group M2, 18.00 ±
0.00; group MH1, 4.33 ± 4.16; and group MH2, 7.00 ±
2.65. Groups C, M1 and M2 did not differ significantly.
Significant differences were observed between groups H
and C, between groups H and M1 or M2, between groups
H and MH1, and between groups M1 or M2 and groups
MH1 or MH2 (*P < 0.05) (Fig. 4, Table 1).
Discussion
This study examined the effects of intra-articular injection
of qniumucin in a rabbit model of OA using resection of
the anterior cruciate ligament. The results were as follows.
First, when qniumucin alone was injected, cartilage
degeneration did not differ from that in the control group.
Second, only minor cartilage degeneration was observed
when a mixture of HA and qniumucin was injected com-
pared with the degeneration present after injection of HA
only. Third, no significant difference in the effects of qniu-
mucin isolated from different species of jellyfish was
apparent in this study.
HA is responsible for the viscosity and elasticity of syno-
vial fluid and thus plays roles in lubrication and shock-
absorption. An increase in low molecular weight HA
reportedly reduces the viscosity and elasticity of synovial
fluid under inflammatory conditions such as OA [17].
However, various other effects have been attributed to
HA, including anti-inflammatory and analgesic effects,
inhibition of cartilage degeneration and an ability to
enhance damage repair [18].
Safranin-O staining reflects the accumulation of prote-
oglycan and acts as an index of cartilage degeneration in
tissues. Although a reduction in safranin-O staining of the
extracellular matrix was seen in our study, cartilage degen-
eration was clearly inhibited in groups H and MH com-
pared with the degeneration observed in group C.
In recent years, a glycoprotein with a mucin region called
lubricin (a superficial zone protein and member of the tri-
bonectin family) has been identified in the synovial fluid
and on the articular surface. The presence of lubricin in
both areas contributes to reductions in articular friction.
This substance is characterized by a mucin-type region in
which O-glycans are connected to the protein backbone,
with nonmucin-type sequences at both ends. This non-
mucin region has been suggested to interact with the car-
tilage surface to facilitate the adherence of lubricin. The
mucin and nonmucin regions are assumed to play differ-
ent roles, with the former extending the sugar chains out-
ward like a brush to reduce friction and the latter
promoting adhesion of lubricin to the cartilage surface.
This is referred to as the "brushing model", based on the
inferred shape of the molecule [19]. No such mechanism
has been suggested for tribonectin, but this substance
shares some common characteristics with lubricin insofar
as it also displays a mucin-type sequence that reduces fric-
tion together with a nonmucin region. The mucin region
is believed to adsorb densely to the cartilage tissue surface
(perhaps as a film) to reduce friction. However, adhesion
of these mucin-type glycoproteins to the articular surface
after injection has yet to be directly confirmed.
Macroscopic findings in the femur of the knee joint 10 weeks  after OA model preparation. Figure 2
Macroscopic findings in the femur of the knee joint 
10 weeks after OA model preparation. a (group C): 
Cartilage defects are observed on both the medial and lateral 
sides. These extend to the subchondral bone and range 
across the entire weight-bearing area. b (group H): Irregular-
ity of the cartilage surface is apparent on both medial and lat-
eral sides in the photo. A cartilage defect extending to the 
subchondral bone can be seen in some sections. c, d (group 
M1, moon jellyfish extract; group M2, Nomura's jellyfish 
extract, respectively): As with group C, a cartilage defect 
extending to the subchondral bone is observed. No differ-
ence is apparent in the range of the defect. e, f (group MH1, 
moon jellyfish extract; group MH2, Nomura's jellyfish 
extract, respectively): Irregularity of the cartilage surface is 
apparent on the medial side in the photo. No exposure of 
the subchondral bone is observed and the range of the defect 
is very limited. No differences are seen in the M or MH 
groups where the qniumucin had been extracted from the 
two different species of jellyfish. Arrowheads indicate areas 
of exposed subchondral bone.BMC Biotechnology 2009, 9:98 http://www.biomedcentral.com/1472-6750/9/98
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Histological findings. Figure 3
Histological findings. The femoral condyle in the knee joint was resected and fixed in 4% neutral-buffered formalin (pH 7.4). 
The tissue was then decalcified with 10% EDTA and the cross-section was embedded in paraffin wax. Dewaxed sections were 
processed for safranin-O (a--f) and toluidine blue (g--l) staining. a (group C): The cartilage defect reaches the subchondral bone. 
b (group H): The fissure in the cartilage extends to the deep layer and reduced staining is observed in the upper layer from the 
tide mark. Cell sequences are not maintained and a reduction in the number of cells is observed. c, d (group M1, moon jellyfish 
extract; group M2, Nomura's jellyfish extract, respectively): Only a small portion of the cartilage layer remains and the cells 
have been obliterated. e, f (group MH1, moon jellyfish extract; group MH2, Nomura's jellyfish extract, respectively): Peeled 
cartilage layers are seen, but fissure have generally extended to the middle layer. Cell sequences are relatively well maintained 
and the reduction in staining is minor compared with that in group H. g (group C): No metachromasia is observed with toluid-
ine blue staining in the cartilage layer. h (group H): Slight metachromasia is observed in the cartilage layer. i, j (group M1, moon 
jellyfish extract; group M2, Nomura's jellyfish extract, respectively): No metachromasia is observed in the cartilage layer. k, l 
(group MH1, moon jellyfish extract; group MH2, Nomura's jellyfish extract, respectively): The cartilage layer shows metachro-
masia with toluidine blue staining, which is specific for articular cartilage. Magnification: a-l, × 4; m-r, × 10.BMC Biotechnology 2009, 9:98 http://www.biomedcentral.com/1472-6750/9/98
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Table 1: Results of post hoc testing (Scheffé's method).
(I) V1 (J) V1 Difference of averages (I-J) SEM P 95% CI
Lower limit Upper limit Figure 5
Group C group MH1 17.6667* 2.3094 .000 11.891 23.443 *2
group MH2 15.0000* 2.3094 .000 9.224 20.776 *1
group H 10.8333* 2.3094 .002 5.057 16.609 *5
group M1 3.3333 2.3094 .233 -2.443 9.109
group M2 4.0000 2.3094 .157 -1.776 9.776
Group H group MH1 6.8333* 2.6822 .024 1.057 12.609 *10
group MH2 4.1667 2.6822 .142 -1.609 9.943
group C -10.8333* 2.6822 .002 -16.609 -5.057 *5
group M1 -7.5000* 2.6822 .015 -13.276 -1.724 *4
group M2 -6.8333* 2.6822 .024 -12.609 -1.057 *3
Group M1 group MH1 14.3333* 0.6667 .000 8.557 20.109 *9
group MH2 11.6667* 0.6667 .001 5.891 17.443 *8
group H 7.5000* 0.6667 .015 1.724 13.276 *4
group C -3.3333 0.6667 .233 -9.109 2.443
group M2 .6667 0.6667 .806 -5.109 6.443
Group M2 group MH1 13.6667* 0.0000 .000 7.891 19.443 *7
group MH2 11.0000* 0.0000 .001 5.224 16.776 *6
group H 6.8333* 0.0000 .024 1.057 12.609 *3
group C -4.0000 0.0000 .157 -9.776 1.776
group M1 -.6667 0.0000 .806 -6.443 5.109
Group group MH2 -2.6667 2.4037 .334 -8.443 3.109
group H -6.8333* 2.4037 .024 -12.609 -1.057 *10
group C -17.6667* 2.4037 .000 -23.443 -11.891 *2
group M1 -14.3333* 2.4037 .000 -20.109 -8.557 *9
group M2 -13.6667* 2.4037 .000 -19.443 -7.891 *7BMC Biotechnology 2009, 9:98 http://www.biomedcentral.com/1472-6750/9/98
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Group MH2 group MH1 2.6667 1.5275 .334 -3.109 8.443
group H -4.1667 1.5275 .142 -9.943 1.609
group C -15.0000* 1.5275 .000 -20.776 -9.224 *1
group M1 -11.6667* 1.5275 .001 -17.443 -5.891 *8
group M2 -11.0000* 1.5275 .001 -16.776 -5.224 *6
SEM, standard error of the mean; CI, confidence interval.
Table 1: Results of post hoc testing (Scheffé's method). (Continued)
Osteoarthritis score Figure 4
Osteoarthritis score. Samples were histologically evaluated based on the standard grading and staging of OA cartilage his-
topathology. Evaluation was quantified using the following formula: most degenerated site in the cartilage (grades 1-6, Table 2) 
× area of degeneration (stages 1-4, Table 3) = OA score (1-24, Table 3). Columns and vertical lines represent mean values and 
standard deviations for each group, respectively. No significant differences were observed between group C and groups M1 and 
M2. Significant differences were observed between groups H and C, between groups H and M1 or M2, between groups H and 
MH1, and between groups M1 or M2 and groups MH1 or MH2. *Significant differences between groups, corresponding to the 
last column in Table 1. After analysis of variance, least significant differences were used for post hoc testing (Scheffé's method). 
Mean OA scores were compared and values of * P < 0.05 were considered significant. Groups M1 and MH1: moon jellyfish 
extract. Groups M2 and MH2: Nomura's jellyfish extract.BMC Biotechnology 2009, 9:98 http://www.biomedcentral.com/1472-6750/9/98
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Mucin or mucin-like substances are likely to form a self-
assembled film (SAF) on both hydrophobic and
hydrophilic surfaces. One significant example of a SAF in
biological systems is the mucin film on the ocular surface
that protects the eyeball [20]. Although the bond created
by each single sugar chain makes only a small contribu-
tion to the total adsorption energy, cooperative interac-
tion of many glycan chains concentrated in a small area
provides a sufficient gain in free energy (and a reduction
in entropy) to immobilize the polymer chain of the
mucin. Adhesion and SAF formation on the surface are
possible without any selective interaction, such as that
suggested for the nonmucin sequence of lubricin, which
may be the first trigger of adhesion. Therefore, if the goal
of treatment is to reduce friction, any kind of mucin that
lacks a nonmucin region could be used instead of lubricin
or tribonectin. Jay mentioned the synergic effects of
lubricin and HA in an in vitro study [12]. Mucin may have
potential synergic effects with HA, as mucin is one com-
ponent of lubricin. In this study, we first demonstrated
that exogenous mucin derived from natural jellyfish
showed synergic effects with HA using an in vivo animal
model. These effects might be induced by improving the
viscosity and friction properties of synovial fluid and
enhancing the self-assembly capacity of cartilage.
Many different kinds of mucins are known. As no large-
scale production of artificial polymeric mucins has been
achieved with biotechnology or chemical synthesis,
extraction from the natural environment remains the
most appropriate method for provision as commercial
substances. Mucins are widely distributed in animals and
plants as components of mucus. For example, in plants
mucins are found in extracts of lotuses, okra and yams.
However, the structure of plant mucins is completely dif-
ferent from that of animal mucins, with a short peptide
connected to long sugar chains, such as galactan and man-
nan [21]. We have therefore focused on animal mucins as
candidate materials for therapeutic injection.
Animal mucins are produced and retained as components
of mucus by all living animals, regardless of taxonomy.
Huge potential variations exist in components such as the
core peptide sequence, nonmucin domain sequence and
structure of the sugar chains (glycoforms) according to the
animal species. However, there are very few examples of
animal mucins that are mass produced by domestic ani-
mals [13]. These are broadly classified as gastric mucins
[22] and submaxillary salivary gland mucins [23,24]. Gas-
tric mucins constitute a mixture harvested from the lavage
fluids of internal organs as low-purity materials. Only
total monosaccharide (for example, sialic acid) and
amino acid analyses have been performed, with no further
characterization, so gastric mucins constitute an inexpen-
sive material suitable for mass production. In contrast,
submaxillary mucins are very pure and detailed structural
analyses of their amino acid sequences and saccharide
compositions have been performed [25]. A monoclonal
antibody directed against submaxillary mucins known as
sialyl Tn antigen has been produced and used as a tumor
marker [26]. However, these animal mucins risk contam-
ination with foreign substances unless thorough purifica-
tion is performed, so use tends to be avoided. For
example, prions causing BSE cannot be eliminated.
Mucins from snails [27], starfish [14] and squid [15] are
currently available on the market, but production vol-
umes are limited. Among these mucin alternatives, qniu-
mucin, which is harvested from jellyfish, was discovered
in recent years by our colleagues [16]. As mass production
is inexpensive, qniumucin is a candidate mucin for wide
application in many patients as a treatment for OA. Qniu-
mucin is characteristically an almost pure monotonously
repeated sequence of short mucin regions called "tandem
repeats". The tandem repeat unit consists of eight amino
acids (sequence VVETTAAP or VIETTAAP) and the sugar
chains are short (usually only 1-3 sugars), with only a few
types of monosaccharides and no sialic acid. Since qniu-
mucin seems to have very few peptide sequences other
than the mucin portion, only mild biological reactions are
expected from the immune system in the form of allergies.
This low potential for biological rejection is a further
advantage of the use of this mucin. The risks involved in
providing a mass product on an industrial scale are thus
significantly reduced.
In a preliminary experiment to test the effects of injection
with qniumucin, no elevation of the blood cell count or
C-reactive protein and no swelling of the joints were
observed (unpublished results). No histological findings
of synovium have been detected among normal and
injected joints (unpublished results). The possibility that
an endogenous endotoxin, identified in this preliminary
experiment, might cause adverse effects is a concern, but
no such effects have yet been observed. After the purifica-
tion method was improved to preclude any contamina-
tion with the solvent from high-performance liquid
chromatography, the concentration of endotoxin in qniu-
mucin purified by ion-exchange chromatography and in
unpurified qniumucin were both <10 EU/ml when char-
acterized by Endosafe-PTS (Charles River Laboratories
Japan, Kanagawa, Japan). Based on these considerations,
we proceeded with the intra-articular injection of this
qniumucin, expecting a friction-reducing effect. The
present results represent a promising step in the develop-
ment of a new treatment for cartilage degeneration.
Conclusion
After injecting a mixture of mucin and HA, cartilage
degeneration was significantly inhibited compared with
that in rabbits injected with HA alone. This effect might beBMC Biotechnology 2009, 9:98 http://www.biomedcentral.com/1472-6750/9/98
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induced by improving the viscosity and friction properties
of the synovial fluid and enhancing the self-assembly
capacity of the cartilage.
Methods
All procedures using animals in this study were performed
in accordance with the Guide for the Care and Use of Lab-
oratory Animals (NIH Publication No. 85-23, revised
1996) published by the National Institutes of Health,
USA, and the Guidelines of Tokai University on Animal
Use.
Reagents
Artz® (Kaken Pharmaceutical, Tokyo, Japan) was used in
making the solution of polymeric HA. The average molec-
ular weight of this HA is approximately 800,000 and the
concentration used was 25 mg/2.5 ml. Qniumucin from
S. nomurai or A. aurita was dissolved in saline at a concen-
tration of 1 mg/ml to create stock solutions.
Extraction and purification of qniumucin
The mesogloea, the major part of the umbrella in jellyfish,
was cut into small pieces and suspended in water. After
removing insoluble material by centrifugation at 10,000 ×
g, one third of the volume of ethanol was added to the
supernatant. The resulting precipitate was harvested by
centrifugation at 10,000 × g and dissolved in water. Super-
natant was collected by centrifugation at 10,000 × g, dia-
lyzed against water, and lyophilized. The lyophilized
material was then dissolved in phosphate buffer and incu-
bated with anion-exchange gel beads (Diethylaminoethyl
(DEAE) - resin, Toyopearl DEAE-650M; Tosoh, Tokyo,
Japan) for 1 h. The beads were washed well with phos-
phate buffer and the bound proteins were eluted with elu-
tion buffer (phosphate buffer, 0.5 M NaCl). The eluent
was collected by filtration, dialyzed against water, and
lyophilized.
Animals
Japanese white rabbits (females weighing 3 kg) were pur-
chased from Tokyo Laboratory Animals Science (Tokyo,
Japan). The rabbits were kept individually and reared in a
fiber-reinforced polymer cage (width 450 mm × height
450 mm × depth 900 mm).
OA model
An ACL-T model [28-34] was prepared for use as the OA
model. With the rabbits under inhalation anesthesia with
isoflurane (Forane®; Abbott Japan, Tokyo, Japan), a 3-cm
incision was made aseptically on the medial side of both
knees to expose the patella and patellar tendon, and the
articular capsule was incised. The patella was then dislo-
cated outwardly to an extended position and the knee
joint was bent for macroscopic resection of the anterior
cruciate ligament. The patella was then repositioned and
the subdermal muscular layer and skin were sutured with
nylon thread.
Experimental design
Eighteen rabbits in which the 36 anterior cruciate liga-
ments had been resected in both knee joints were divided
randomly into four groups: a control (C) group (injected
with saline; six knees), an HA-only group (H group; six
knees), two qniumucin-only groups (M1:S. nomurai,
M2:A. aurita group; six knees each) and two qniumucin +
HA groups (MH1 and MH2 groups; six knees each). Each
treatment comprised 1 ml per intra-articular injection.
Purified qniumucin from S. nomurai or A. aurita was used
at 1 mg/ml. Mixtures of HA solution (0.5 ml) + saline (0.5
ml), qniumucin solution (0.5 ml) + saline (0.5 ml) and
qniumucin solution (0.5 ml) + HA solution (0.5 ml) were
injected into the H, M and MH groups, respectively, after
resection of the anterior cruciate ligament. These four
treatments were given at intervals of 7 days, starting from
week 4 after surgery (thus in weeks 4, 5, 6, 7 and 8; Fig. 5).
With each rabbit under isoflurane inhalation anesthesia,
the intra-articular injection was made into the upper mar-
gin of the lateral patella in the rabbit knee joint, using a
syringe with a 26-G needle (Terumo, Tokyo, Japan). All
rabbits were killed by pentobarbiturate overdose (Nemb-
utal®; Dainippon Sumitomo Pharma, Osaka, Japan) in
week 10 after resection (Fig. 5).
Macroscopic and histological evaluation of the articular 
cartilage
The femoral knee joint was checked immediately after the
rabbits had been killed. The femora of both knee joints
were resected and fixed in 4% neutral-buffered formalin
(pH 7.4). Fixed samples were decalcified with 10% ethyl-
ene diaminetetraacetic acid (EDTA) (pH 7.4) and then
embedded in paraffin wax. Sections cut in the sagittal
plane of the femoral condyle were dewaxed, prepared and
Protocol Figure 5
Protocol. Intra-articular injections were commenced from 
week 4 after preparation of the osteoarthritis (OA) model. 
Treatment solutions were injected once weekly until week 8. 
The rabbits were killed 10 weeks after surgery. Surgery and 
intra-articular injections were performed with the rabbits 
under general anesthesia. ACL-T, anterior cruciate ligament 
transection.BMC Biotechnology 2009, 9:98 http://www.biomedcentral.com/1472-6750/9/98
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stained with safranin-O and toluidine blue. Samples were
evaluated histologically based on the standard grading
and staging of OA cartilage histopathology [35]. Evalua-
tion was quantified with the following formula: most
degenerated site in the cartilage (grades 1-6, Table 2) × the
area of degeneration (stage 1-4, Table 3) = OA score (1-24,
Table 3).
Statistical analysis
After analysis of variance, the least significant differences
were used for post hoc testing (Scheffé's method). Average
OA scores were compared and values of P < 0.05 were con-
sidered significant.
List of abbreviations
OA: osteoarthritis; HA: hyaluronic acid; NSAIDs: nonster-
oidal anti-inflammatory drugs; BSE: bovine spongiform
Table 2: OA cartilage histopathology grade assessment; grading methodology
Grade (key feature) Associated criteria (tissue reaction
Grade 1: surface intact Matrix: superficial zone intact, oedema and/or superficial fibrillation (abrasion), focal superficial matrix 
condensation
Cells: death, proliferation (clusters), hypertrophy, superficial zone Reaction must be more than superficial 
fibrillation only
Grade 2: surface discontinuity As above
+ Matrix discontinuity at superficial zone (deep fibrillation)
± Cationic stain matrix depletion (Safranin O or Toluidine Blue) upper 1/3 of cartilage
± Focal perichondronal increased stain (mid zone)
± Disorientation of chondron columns
Cells: death, proliferation (clusters), hypertrophy
Grade 3: vertical fissures (clefts) As above
Matrix vertical fissures into mid zone, branched fissures
± Cationic stain depletion (Safranin O or Toluidine Blue) into lower 2/3 of cartilage (deep zone)
± New collagen formation (polarized light microscopy, Picro Sirius Red stain)
Cells: death, regeneration (clusters), hypertrophy, cartilage domains adjacent to fissures
Grade 4: erosion Cartilage matrix loss: delamination of superficial layer, mid layer cyst formation
Excavation: matrix loss superficial layer and mid zone
Grade 5: denudation Surface: sclerotic bone or reparative tissue including fibrocartilage within denuded surface. Microfracture with 
repair limited to bone surface
Grade 6: deformation Bone remodelling (more than osteophyte formation only). Includes: microfracturewith fibrocartilaginous and 
osseous repair extending above the previous surface
Grade = depth progression into cartilage.
Table 3: OA score; semi-quantitative method
Stage % Involvement (surface, area, volume)
Grade (key feature) Stage 1 <10% Stage 2 10-25% Stage 3 25-50% Stage 4 >50%
Grade 1(surface intact) 1 2 3 4
Grade 2 (surface discontinuity) 2 4 6 8
Grade 3 (vertica fissures, clefts) 3 6 9 12
Grade 4 (erosion) 4 8 12 16
Grade 5(denudation) 5 10 15 20
Grade 6(deformation) 6 12 18 24
Score = grade × stage.BMC Biotechnology 2009, 9:98 http://www.biomedcentral.com/1472-6750/9/98
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encephalopathy; ACL-T: anterior cruciate ligament trans-
action; EDTA: ethylene diaminetetraacetic acid; SAF: self-
assembled film.
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